CERAMENT-BC
Financiado
A novel bone implant with enhanced bone healing capacity
The objective of the project is to bring the first bone implant with enhanced bone healing capacity to the market and clinical practice. The market demand for bone implants is steadily increasing driven by aging populations, incre...
The objective of the project is to bring the first bone implant with enhanced bone healing capacity to the market and clinical practice. The market demand for bone implants is steadily increasing driven by aging populations, increased demand for high quality of life and an increasing number of joint reconstruction surgeries. Enhancement of the bone healing process is often necessary, especially for patients with larger bone voids and gaps. The existing clinical methods targeting this need are based on the combination of Bone Graft Substitutes (BGS) with:
• systemic treatment with Bone Active Drug (BAD), or
• the off-label use of the BAD.
Both alternatives create risks for side-effects and complications.
BONESUPPORT will move beyond the current state of the art and propose CERAMENT-BC – the first product combining a BGS with a BAD (bisphosphonate), enhancing the healing capacity of the implant. The commercial potential of this nano-modified material lies in the efficient local delivery of the drug to the targeted skeletal side, minimizing side-effects and improving quality of life for the patient.
The targeted users are orthopedic surgeons who need new methods for the enhancement of the bone healing process, reduction of secondary fractures and postoperative complications. CERAMENT-BC will meet those needs by combining the advantages of BGS and BAD and thus providing both fracture stability and a local therapeutic effect.
The Phase 1 study will develop a business plan for the commercialisation of the product. Assuring cost-efficient and innovative approaches to the treatment of musculoskeletal conditions is an EU-wide challenge. The project will address this challenge by proposing a new treatment option which for the first time combines an injectable biomaterial with a BAD.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2016-08-22
Fecha Fin: 2017-02-28
Fecha Fin: 2017-02-28
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2017-02-28
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
BONE SUPPORT AB
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
695.12K€ |
Participante